(VIANEWS) – Xylem (XYL), Progyny (PGNY), First Community Bankshares (FCBC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Xylem (XYL)
40.3% sales growth and 10.95% return on equity
Xylem Inc., together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally. It operates through three segments: Water Infrastructure, Applied Water, and Measurement & Control Solutions. The Water Infrastructure segment offers various products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the Flygt, Godwin, Sanitaire, Leopold, Wedeco, and Xylem Vue brand names for the transportation and treatment of water. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, Xylem Vue, and Flojet brand names for residential and commercial building services, and industrial water applications. The Measurement & Control Solutions segment offers smart meters, networked communication devices, data analytics, test equipment, controls, sensor devices, software and managed services, and critical infrastructure services; and software and services, including cloud-based analytics, remote monitoring and data management, leak detection, condition assessment, asset management, and pressure monitoring solutions, as well as testing equipment. This segment sells its products under the Pure Technologies, Sensus, Smith Blair, WTW, Xylem Vue, and YSI brand names. The company markets and sells its products through a network of direct sales force, resellers, distributors, and value-added solution providers. Xylem Inc. was formerly known as ITT WCO, Inc. and changed its name to Xylem Inc. in May 2011. Xylem Inc. was incorporated in 2011 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, Xylem has a trailing twelve months EPS of $2.05.
PE Ratio
Xylem has a trailing twelve months price to earnings ratio of 54.97. Meaning, the purchaser of the share is investing $54.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.95%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.8%, now sitting on 5.7B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xylem’s EBITDA is 102.12.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 25, 2023, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 1.15%.
Previous days news about Xylem(XYL)
- Xylem (xyl) Q2 earnings & revenues top estimates, '23 view up. According to Zacks on Wednesday, 2 August, "Exiting the second quarter, Xylem had cash and cash equivalents of $708 million compared with $944 million at the end of December 2022. ", "In the first six months of 2023, Xylem paid dividends of $139 million, up 26.4% year over year. "
2. Progyny (PGNY)
35.9% sales growth and 12.23% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.43.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 91.58. Meaning, the purchaser of the share is investing $91.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.23%.
Moving Average
Progyny’s value is higher than its 50-day moving average of $38.43 and way above its 200-day moving average of $35.35.
3. First Community Bankshares (FCBC)
13.3% sales growth and 11.43% return on equity
First Community Bankshares, Inc. operates as the financial holding company for First Community Bank that provides various banking products and services. It offers demand deposit accounts, savings and money market accounts, certificates of deposit, and individual retirement arrangements; commercial, consumer, and real estate mortgage loans, as well as lines of credit; various credit and debit cards, and automated teller machine card services; and corporate and personal trust services. The company also provides wealth management services, including trust management, estate administration, and investment advisory services; and investment management services. It serves individuals and businesses across various industries, such as education, government, and health services; coal mining and gas extraction; retail trade; construction; manufacturing; tourism; and transportation. As of December 31, 2021, the company operated 49 branches, including 17 branches in West Virginia, 23 branches in Virginia, 7 branches in North Carolina, and 2 branches in Tennessee. First Community Bankshares, Inc. was founded in 1874 and is headquartered in Bluefield, Virginia.
Earnings Per Share
As for profitability, First Community Bankshares has a trailing twelve months EPS of $2.98.
PE Ratio
First Community Bankshares has a trailing twelve months price to earnings ratio of 10.57. Meaning, the purchaser of the share is investing $10.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.43%.
4. Halozyme Therapeutics (HALO)
6.4% sales growth and 111.4% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.27.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 31.71. Meaning, the purchaser of the share is investing $31.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 111.4%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Halozyme Therapeutics’s EBITDA is 82.71.
Sales Growth
Halozyme Therapeutics’s sales growth is 30.8% for the present quarter and 6.4% for the next.
Volume
Today’s last reported volume for Halozyme Therapeutics is 2627950 which is 121.47% above its average volume of 1186580.
